NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Oculis Holding AG ("Oculis" or the "Company") (NASDAQ: OCS). Such investors are advised to...
Oculis Holding AG shares lost over 23% of their value in a single session after Phase 3 DIAMOND trial results revealed OCS-01 failed to meet its primary endpoint in diabetic macular edema.
Oculis Holding AG claimed its "most important" drug, OSC-01, was biologically approved months before revealing the Phase 3 Diamond studies concerning the drug had failed to achieve their primary endpoints....
Oculis Holding AG SEC filings continued to describe the OCS-01 DME program as on track for FDA submission after Phase 3 DIAMOND trials had already failed -- shares fell over 23%
New York, New York--(Newsfile Corp. - June 1, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Oculis Holding AG ("Oculis Holding AG") (NASDAQ: OCS) concerning potential...
Oculis (NASDAQ:OCS) said its two Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema did not meet their primary endpoints, and the company does not currently plan to pursue a U.S. Food and Drug...
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.62%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.99%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.94%. March E-mini...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.49%. March E-mini S&P futures (ESH26...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.32%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.16%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.63%. March E-mini S&P futures (ESH26...
Chardan Capital analyst Daniil Gataulin maintained a Buy rating on Oculis Holding today and set a price target of $51.00. The company’s shares closed yesterday at $19.06.Elevate Your Investing Strategy:...